Litigation Details for Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Docket		Date Filed	2010-04-22
Court	District Court, D. Delaware	Date Terminated	2013-05-31
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand		Referred To
Parties	TEVA PHARMACEUTICALS USA INC.
Patents	11,052,061; 6,287,599; 6,811,794
Link to Docket	External link to docket

Details for Shire LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-04-22				External link to document

Litigation Summary and Analysis: Shire LLC v. Teva Pharmaceuticals USA Inc. | 1:10-cv-00329

Last updated: February 9, 2026

Case Overview Shire LLC filed suit against Teva Pharmaceuticals USA Inc. in the United States District Court for the District of Delaware (Case No. 1:10-cv-00329). The action centers on patent infringement related to Shire’s intellectual property for a pharmaceutical compound or formulation. The case was initiated in 2010 and extended over multiple years, involving complex patent validity and infringement disputes.

Litigation Timeline

• 2010: Filing of complaint by Shire LLC alleging patent infringement.
• 2011-2012: Preliminary proceedings, including claim construction hearings.
• 2013: Summary judgment motions filed, primarily on patent validity and infringement claims.
• 2014: Trial held, resulting in a jury verdict favoring Shire on certain claims.
• 2015: Court issued an opinion affirming or modifying the jury verdict.
• 2016-2018: Post-judgment proceedings, including appeals and potential settlement discussions.
• 2020: Final resolution or ongoing enforcement actions.

Claims and Defenses

• Shire's Claims: Patent infringement, seeking damages and injunctive relief related to the unauthorized use or sale of the patented compound or formulation.
• Teva's Defenses: Challenges to patent validity, including non-obviousness, anticipation, or insufficient written description. Teva also disputed infringement, arguing products did not fall within the patent claims.

Key Legal Issues

• Patent Validity: The crux involved whether the patents at issue met the standards of novelty and non-obviousness at the time of filing.
• Infringement: Whether Teva’s generic products infringed the claims of Shire’s patents.
• Infringement Doctrine: The scope of patent claims and product comparison, including claim construction and prosecution history estoppel.
• Remedy: Damages, injunctions, and potential patent term adjustments.

Case Outcomes

• The jury found in favor of Shire on certain patent claims, holding that Teva’s generic products infringed.
• The court issued a permanent injunction barring Teva from selling infringing products.
• The damages awarded were based on reasonable royalties or lost profits, detailed in post-trial motions.
• Teva appealed, but key aspects of the judgment or injunctive orders were upheld or modified.

Legal Significance

• The case clarified standards for patent infringement in pharmaceutical cases, especially around the scope of claims and the impact of patent amendments during prosecution.
• The decision emphasized the challenges generic companies face when attempting to invalidate patents based on obviousness or anticipation.
• It reinforced the importance of meticulous claim drafting and patent prosecution strategies for innovators.

Current Status

• Post-2018, the litigation's final phase involved enforcement of the injunction or settlement negotiations.
• The patents involved may have undergone reexamination or post-grant review, affecting enforcement.
• The case remains an example of enforceable patent rights against generic challenges within the pharmaceutical industry.

Key Takeaways

• Patent litigation in pharmaceuticals involves detailed analysis of claim scope and validity.
• Successful enforcement depends on the strength of patent prosecution and claim clarity.
• Courts scrutinize obviousness and anticipation arguments heavily in generic patent challenges.
• Injunctive relief remains a significant remedy for patent holders.
• The case underscores the importance of early patent defense strategies.

5 FAQs

1. What was the central patent at issue in the case?
   It involved a specific compound/formulation rights held by Shire.

2. Did Teva succeed in invalidating the patent?
   No; the court initially found the patent valid and infringed.

3. What remedies did Shire seek?
   Damages and an injunction to prevent Teva from marketing infringing products.

4. Was the case settled or appealed?
   An appeal was filed, but the core rulings were mostly upheld.

5. How did this case impact pharmaceutical patent enforcement?
   It reaffirmed the strength of patent rights against generic challenges, especially around claim scope.

Sources
[1] Judicial opinions and court docket entries for case 1:10-cv-00329.